Refer to important disclosures at the end of this report





DBS

Heritage Foods



Your success is our success

CMP Rs725 **Target Price** Rs770(▲)

Rating ACCUMULATE (=) **Upside** 5.7 %

Operating efficiencies to improve margins

- Heritage Dairy's (Heritage) consolidated revenue grew by 14%, 7% below of our estimate. EBITDA grew by 50%, 10% ahead of our expectation and PAT grew by 80%, in line with our estimate.
- Dairy business' 14% growth was driven by 17% growth in VADP (value added dairy products). Liquid milk business grew by 13%. We believe that Heritage's organic dairy business (excluding Reliance dairy) grew by ~5%.
- Gross margin improved by 290bps due to improvement in operating efficiency of Reliance dairy. However, EBITDA margin improved by only 190bps due to higher overheads.
- We expect sales/earnings CAGR of 16%/54% and margin improvement of 210bps over FY18-20E with growing contribution from VADP and improvement in efficiency. We maintain our ACCUMULATE stance with a Target Price (TP) of Rs770, now valuing it at 15x FY20E EV/EBITDA.
- VADP drives revenue growth: Heritage's consolidated revenue grew by 14%, 7% below our estimate. The Dairy business grew by 14% on the back of 17% growth in VADP (22% of the Dairy business). In VADP, the Curd business (82% of the VADP business) grew by 21% to Rs1bn. The Liquid Milk business (78% of the Dairy business) grew by 14%, largely driven by the Reliance Dairy acquisition. We believe that Heritage's organic growth (ex-Reliance Dairy) grew by ~5%. Milk procurement increased by 24% to 13.2 llpd due to inorganic growth. The management continues to focus on VADP and aspires to increase its contribution to 40% (from 22% in FY18) by 2022E.
- Improving operational efficiency of Reliance Dairy drives margins: Gross margin expanded by 290bps due to improving efficiency at Reliance Dairy. The company has rationalized Reliance Dairy operations by reducing third-party processing, sharpening focus on direct milk procurement and consolidating milk processing & chilling centers. EBITDA growth of 51% was 10% ahead of our estimate, with margin expansion of 190bps. Lower-than-expected other income and higher-than-expected depreciation charges led to APAT growth of 80% - in line with our expectations.
- Valuations: We appreciate the management's effort to improve efficiency of Reliance Dairy by rationalizing operations and increasing contribution from VADP. On the back of this effort, we expect Heritage's VADP contribution to increase from 22% to 25% and margin to improve by 210bps over FY18-20E. We maintain our ACCUMULATE stance with a TP of Rs770, now valuing the company at 15x FY20E EV/ EBITDA.

Financial Snapshot (Consolidated)

(Rs mn)	FY16	FY17	FY18	FY19E	FY20E
Revenue	23,806	26,429	23,731	28,111	32,153
EBITDA	1,308	1,413	1,304	2,056	2,449
EBITDA Margin (%)	5.5	5.3	5.5	7.3	7.6
APAT	568	668	548	1,020	1,298
EPS (Rs)	12.2	14.4	11.8	22.0	28.0
EPS (% chg)	101.5	17.6	(17.9)	86.0	27.2
ROE (%)	26.3	24.7	10.2	12.5	14.4
P/E (x)	59.2	50.3	61.3	33.0	25.9
EV/EBITDA (x)	26.2	24.5	27.2	17.1	14.1
P/BV (x)	14.0	11.2	4.3	3.9	3.5

Source:	Company.	Emkav	Research

%) (9)/(5)
4.6
12
ACCUMULATE

EPS Estimates

Emkay vs Consensus

	FY19E	FY20E
Emkay	22.0	28.0
Consensus	20.0	25.9
Mean Consensus TP (1	12M)	Rs884
Stock Details		
Bloomberg Code		HTFL IN
Face Value (Rs)		5
Shares outstanding (mr	า)	46
52 Week H/L		889 /520
M Cap (Rsbn/USD bn)		34 / 0.50
Daily Avg Volume (nos.	.)	48,778
Daily Avg Turnover (US	\$\$ mn)	0.5

Shareholding Pattern War 16	
Promoters	39.9%
Fils	8.7%
DIIs	8.9%
Public and Others	42.5%

Sharoholding Dattorn Mar 119

Price Performance								
(%)	1M	3M	6M	12M				
Absolute	3	8	(1)	28				
Rel. to Nifty	3	6	(4)	15				

Relative price chart



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

Ashit Desai

ashit.desai@emkayglobal.com

+91-022-66121340

Dhiraj Mistry, CFA

dhiraj.mistry@emkayglobal.com +91-22-66121281

Exhibit 1: Actual vs estimates

Damir	Astual	Estimate		% var	iation	
Rsmn	Actual	Emkay	Consensus	Emkay	Consensus	Comment
Revenues	5616.3	6058.8	6516.5	-7.3%	-13.8%	
EBITDA	447.5	408.2	449.3	9.6%	-0.4%	Operating efficiencies drive margin
EBITDA Margin (%)	8.0%	6.7%	6.9%	123	107	
APAT	203.6	201.1	225.5	1.2%	-9.7%	

Source: Company, Emkay Research

Exhibit 2: Revision in earnings estimates

V/F Max/Da		FY19E		FY20E			
Y/E, Mar (Rs. mn)	Earlier	Revised	% Change	Earlier	Revised	% Change	
Revenues	28,497	28,111	(1.4)	32,125	32,153	0.1	
EBITDA	2,090	2,056	(1.6)	2,516	2,449	(2.7)	
EBITDA Margin (%)	7.3	7.3	0 bps	7.7	7.6	-10 bps	
APAT	1,124	1,020	(9.2)	1,365	1,298	(4.9)	
EPS	24.2	22.0	(9.1)	29.4	28.0	(4.9)	

Source: Company, Emkay Research

Exhibit 3: Quarterly performance (Consolidated)

Y/E, Mar (Rs. mn)	Q4FY17	Q3FY18	Q4FY18	YoY (%)	QoQ (%)	FY17	FY18	Gr (%)
Revenue	4,940	5,789	5,616	13.7	-3.0	18,941	23,731	25.3
Expenditure	4,643	5,413	5,169	11.3	-4.5	17,479	22,427	28.3
Consumption of RM	3,976	4,624	4,356	9.5	-5.8	14,971	19,194	28.2
as % of sales	80.5	79.9	77.6			79.0	80.9	
Employee Cost	233	310	303	29.8	-2.4	998	1,242	24.4
as % of sales	4.7	5.4	5.4			5.3	5.2	
Other expenditure	433	479	510	17.7	6.5	1,510	1,991	31.9
as % of sales	8.8	8.3	9.1			8.0	8.4	
EBITDA	297	376	447	50.5	19.0	1,463	1,304	-10.9
Depreciation	63	96	103	64.8	8.0	250	378	51.5
EBIT	235	281	344	46.7	22.7	1,213	925	-23.7
Other Income	17	11	33	92.1	197.5	42	77	84.4
Interest	42	48	56	32.1	16.3	97	182	88.0
PBT	210	244	322	53.3	32.0	1,157	820	-29.2
Total Tax	97	77	118	22.5	54.4	324	271	-16.3
Adjusted PAT	113	167	204	79.6	21.7	833	548	-34.2
Extra ordinary items	2076	0	-4	-100.2	NA	2076	79	NA
Reported PAT	2,189	167	200	-90.9	19.3	2,909	628	-78.4
Adjusted EPS	2.4	3.6	4.4	78.8	21.3	18.0	11.8	-34.3

Margins (%)				(bps)	(bps)			(bps)
Gross Margin	19.5	20.1	22.4	290	230	21.0	19.1	-180
EBIDTA	6.0	6.5	8.0	190	150	7.7	5.5	-220
EBIT	4.8	4.8	6.1	140	130	6.4	3.9	-250
EBT	4.3	4.2	5.7	150	150	6.1	3.5	-270
PAT	2.3	2.9	3.6	130	70	4.4	2.3	-210
Effective Tax rate	46.0	31.4	36.8	-920	530	28.0	33.1	510

Source: Company, Emkay Research

Emikay Research is also available on www.emikayglobal.com, Bloomberg EMIKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Ple Ltd, its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

Key Financials (Consolidated)

Income Statement

Y/E Mar (Rs mn)	FY16	FY17	FY18	FY19E	FY20E
Revenue	23,806	26,429	23,731	28,111	32,153
Expenditure	22,498	25,016	22,427	26,055	29,704
EBITDA	1,308	1,413	1,304	2,056	2,449
Depreciation	345	378	378	457	515
EBIT	963	1,035	925	1,599	1,934
Other Income	65	60	77	96	120
Interest expenses	155	112	182	195	145
PBT	874	983	820	1,500	1,908
Tax	306	314	271	480	611
Extraordinary Items	0	0	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	568	668	548	1,020	1,298
Adjusted PAT	568	668	548	1,020	1,298

Balance Sheet

Y/E Mar (Rs mn)	FY16	FY17	FY18	FY19E	FY20E
Equity share capital	232	232	232	232	232
Reserves & surplus	2,167	2,775	7,545	8,293	9,293
Net worth	2,399	3,007	7,777	8,525	9,525
Minority Interest	0	0	106	106	106
Loan Funds	1,051	1,403	2,464	1,864	1,364
Net deferred tax liability	187	198	180	180	180
Total Liabilities	3,637	4,607	10,527	10,676	11,175
Net block	3,120	2,971	4,331	5,131	5,931
Investment	8	1,488	5,761	5,761	5,761
Current Assets	2,524	2,032	2,625	2,328	2,494
Cash & bank balance	453	470	688	410	476
Other Current Assets	29	19	175	115	132
Current liabilities & Provision	2,112	1,962	2,277	2,632	3,098
Net current assets	413	70	348	(304)	(604)
Misc. exp	0	0	0	0	0
Total Assets	3,637	4,608	10,527	10,676	11,175

Cash Flow

Y/E Mar (Rs mn)	FY16	FY17	FY18	FY19E	FY20E
PBT (Ex-Other income) (NI+Dep)	874	923	743	1,404	1,789
Other Non-Cash items	45	48	0	0	0
Chg in working cap	418	371	(77)	373	367
Operating Cashflow	1,541	1,545	955	1,949	2,205
Capital expenditure	(665)	(211)	(1,747)	(1,257)	(1,315)
Free Cash Flow	876	1,333	(792)	692	890
Investments	0	(1,480)	(4,273)	0	0
Other Investing Cash Flow	(134)	(50)	4,571	0	0
Investing Cashflow	(733)	(1,682)	(1,372)	(1,161)	(1,195)
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	(523)	352	1,061	(600)	(500)
Dividend paid (incl tax)	(85)	(85)	(244)	(271)	(299)
Other Financing Cash Flow	0	0	0	0	0
Financing Cashflow	(762)	155	635	(1,066)	(944)
Net chg in cash	45	17	218	(278)	66
Opening cash position	408	453	470	688	410
Closing cash position	453	470	688	410	476
Source: Company, Emkay Research					

Source: Company, Emkay Research

Emikay Research is also available on www.emikayglobal.com, Bloomberg EMIKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Ple Ltd, its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

Key Ratios

Profitability (%)	FY16	FY17	FY18	FY19E	FY20E
EBITDA Margin	5.5	5.3	5.5	7.3	7.6
EBIT Margin	4.0	3.9	3.9	5.7	6.0
Effective Tax Rate	35.0	32.0	33.1	32.0	32.0
Net Margin	2.4	2.5	2.3	3.6	4.0
ROCE	28.1	26.6	13.2	16.0	18.8
ROE	26.3	24.7	10.2	12.5	14.4
RoIC	30.7	36.6	28.2	38.0	41.7

Per Share Data (Rs)	FY16	FY17	FY18	FY19E	FY20E
EPS	12.2	14.4	11.8	22.0	28.0
CEPS	19.7	22.6	20.0	31.8	39.1
BVPS	51.7	64.8	167.6	183.7	205.3
DPS	1.8	1.8	5.3	5.9	6.4

Valuations (x)	FY16	FY17	FY18	FY19E	FY20E
PER	59.2	50.3	61.3	33.0	25.9
P/CEPS	35.2	30.7	34.6	21.7	17.7
P/BV	14.0	11.2	4.3	3.9	3.5
EV / Sales	1.4	1.3	1.5	1.2	1.1
EV / EBITDA	26.2	24.5	27.2	17.1	14.1
Dividend Yield (%)	0.3	0.3	0.7	0.8	0.9

Gearing Ratio (x)	FY16	FY17	FY18	FY19E	FY20E
Net Debt/ Equity	0.2	0.3	0.2	0.2	0.1
Net Debt/EBIDTA	0.5	0.7	1.4	0.7	0.4
Working Cap Cycle (days)	(0.6)	(5.5)	(5.2)	(9.3)	(12.3)

Growth (%)	FY16	FY17	FY18	FY19E	FY20E
Revenue	14.8	11.0	(10.2)	18.5	14.4
EBITDA	59.4	8.0	(7.7)	57.7	19.1
EBIT	100.4	7.5	(10.6)	72.8	20.9
PAT	101.5	17.6	(17.9)	86.0	27.2

Quarterly (Rs mn)	Q4FY17	Q1FY18	Q2FY18	Q3FY18	Q4FY18
Revenue	4,940	6,164	6,161	5,789	5,616
EBITDA	297	269	211	376	447
EBITDA Margin (%)	6.0	4.4	3.4	6.5	8.0
PAT	2,189	103	74	167	200
EPS (Rs)	47.2	2.2	1.6	3.6	4.3

Source: Company, Emkay Research

Shareholding Pattern (%)	Mar-17	Jun-17	Sep-17	Dec-17	Mar-18
Promoters	39.9	39.9	39.9	39.9	39.9
FIIs	7.2	7.4	8.2	8.5	8.7
DIIs	5.8	6.0	6.0	7.5	8.9
Public and Others	47.1	46.7	45.9	44.2	42.5

Source: Capitaline


Emkay Research is also available on www.emkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd, its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
13-Nov-17	689	736	12m	Accumulate	Sameep Kasbekar
16-Aug-17	664	663	12m	Accumulate	Dhaval Mehta
30-May-17	544	580	12m	Accumulate	Dhaval Mehta
27-Jan-17	492	550	12m	Buy	Dhaval Mehta
03-Jan-17	440	524	12m	Buy	Dhaval Mehta

Source: Company, Emkay Research

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

Emkay Rating Distribution

BUY Expected total return (%) (Stock price appreciation and dividend yield) of over 25% within the next 12-18 months.

ACCUMULATE Expected total return (%) (Stock price appreciation and dividend yield) of over 10% within the next 12-18 months.

Expected total return (%) (Stock price appreciation and dividend yield) of upto 10% within the next 12-18 months.

REDUCE Expected total return (%) (Stock price depreciation) of upto (-) 10% within the next 12-18 months.

SELL The stock is believed to underperform the broad market indices or its related universe within the next 12-18 months.

Completed Date: 28 May 2018 22:26:00 Dissemination Date: 28 May 2018 22:27:00

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayqlobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

Emikay Research is also available on www.emikayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Ple Ltd, its respective connected and associated corporations and affiliates are the distributors of the research report or research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

ED: HEMANT MARADIA SA: DHANANJAY SINHA May 28, 2018 | 6

GENERAL DISCLOSURE/DISCLAIMER BY DBS BANK LTD AS DISTRIBUTOR OF THE RESEARCH REPORT

This report is solely intended for the clients of DBS Bank Ltd,its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS Bank Ltd.

The research set out in this report is based on information obtained from sources believed to be reliable, but we (which collectively refers to DBS Bank Ltd, its respective connected and associated corporations, affiliates and their respective directors, officers, employees and agents (collectively, the "DBS Group") have not conducted due diligence on any of the companies, verified any information or sources or taken into account any other factors which we may consider to be relevant or appropriate in preparing the research. Accordingly, we do not make any representation or warranty as to the accuracy, completeness or correctness of the research set out in this report. Opinions expressed are subject to change without notice. This research is prepared for general circulation. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate independent legal or financial advice. The DBS Group accepts no liability whatsoever for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from any use of and/or reliance upon this document and/or further communication given in relation to this document. This document is not to be construed as an offer or a solicitation of an offer to buy or sell any securities. The DBS Group, along with its affiliates and/or persons associated with any of them may from time to time have interests in the securities mentioned in this document. The DBS Group, may have positions in, and may effect transactions in securities mentioned herein and may also perform or seek to perform broking, investment banking and other banking services for these companies. Any valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report, and there can be no assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments. The information in this document is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed, it may not contain all material information concerning the company (or companies) referred to in this report and the DBS Group is under no obligation to update the information in this report. This publication has not been reviewed or authorized by any regulatory authority in Singapore, Hong Kong or elsewhere. There is no planned schedule or frequency for updating research publication relating to any issuer.

The valuations, opinions, estimates, forecasts, ratings or risk assessments described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein IS NOT TO BE RELIED UPON as a representation and/or warranty by the DBS Group (and/or any persons associated with the aforesaid entities), that: (a) such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and (b) there is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein. Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets. Any assumptions made in this report that refers to commodities, are for the purposes of making forecasts for the company (or companies) mentioned herein. They are not to be construed as recommendations to trade in the physical commodity or in the futures contract relating to the commodity referred to in this report.

DBSVUSA, a US-registered broker-dealer, does not have its own investment banking or research department, has not participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months and does not engage in market-making.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

Emkay Research is also available on www.emkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) PIe Ltd, its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

ED: HEMANT MARADIA SA: DHANANJAY SINHA May 28, 2018 17

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of May 28, 2018
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of May 28, 2018.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the May 28, 2018
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the May 28, 2018

Emkay Research is also available on www.emkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd, its respective connected and associated corporations and affiliates are the distributors of the research report or research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

ED: HEMANT MARADIA SA: DHANANJAY SINHA May 28, 2018 | 8

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY DBS BANK LTD AS DISTRIBUTOR OF THE RESEARCH REPORT

- 1. DBS Bank Ltd., DBS HK, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), DBSV HK or their subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of.
- 2. Neither DBS Bank Ltd, DBS HK nor DBSV HK market makes in equity securities of the issuer(s) or company(ies) mentioned in this Research Report.

Compensation for investment banking services:

3. DBSVUSA, does not have its own investment banking or research department, nor has it participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months. Any US persons wishing to obtain further information, including any clarification on disclosures in this disclaimer, or to effect a transaction in any security discussed in this document should contact DBSVUSA exclusively.

Disclosure of previous investment recommendation produced:

4. DBS Bank Ltd. DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by DBS Bank Ltd. DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates in the preceding 12 months.

RESTRICTIONS ON DISTRIBUTION

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Australia. This report is not for distribution into Hong Kong.
0 0	This report is hot for distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Indonesia Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is not for distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at PO Box 506538, 3rd Floor, Building 3, East Wing, Gate Precinct, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

Emkay Research is also available on www.emkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pie Ltd, its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

SINGAPORE

DBS Bank Ltd

Contact: Janice Chua

12 Marina Boulevard, Marina Bay Financial Centre Tower 3

Singapore 018982 Tel. 65-6878 8888 Fax: 65 65353 418

e-mail: equityresearch@dbs.com Company Regn. No. 196800306E

THAILAND

DBS Vickers Securities (Thailand) Co Ltd

Contact: Chanpen Sirithanarattanakul 989 Siam Piwat Tower Building,

9th, 14th-15th Floor

Rama 1 Road, Pathumwan, Nagkok Thailand 10330 Tel. 66 2 857 7831

Fax: 66 2 658 1269

e-mail: research@th.dbs.com Company Regn. No 0105539127012

Securities and Exchange Commission, Thailand

INDONESIA

PT DBS Vickers Sekuritas (Indonesia)

Contact: Maynard Priajaya Arif

DBS Bank Tower Ciputra World 1, 32/F Jl. Prof. Dr. Satrio Kav. 3-5 Jakarta 12940, Indonesia Tel. 62 21 3003 4900

Fax: 62 21 3003 4943

e-mail: research@id.dbsvickers.com

May 28, 2018| 11



Ashit Desai, PGDM, FRM ashit.desai@emkayglobal.com +91-022-66121340